Literature DB >> 28925394

Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer.

T Ando1, D Charindra1, M Shrestha1, H Umehara1, I Ogawa2, M Miyauchi1, T Takata1.   

Abstract

Tissue inhibitor of metalloproteinase-1 (TIMP-1), a member of the TIMP family (TIMP-1 to 4), is highly expressed in various types of cancer and forms a complex with its receptor CD63 and Integrin β1. However, the precise oncogenic mechanism of TIMP-1 remains unclear. Yes-associated protein (YAP) and transcriptional co-activator with PDZ binding motif (TAZ) are transcription co-activators enhancing the transcription of specific genes related to cell proliferation. But the mechanism of aberrant YAP/TAZ activation in cancer is not fully understood. Here, we showed that TIMP-1 activates YAP/TAZ as novel downstream targets to promote cell proliferation. The TIMP-1-CD63-Integrin β1 axis activates Src and promotes RhoA-mediated F-actin assembly, leading to LATS1/2 inactivation. This results in under-phosphorylation, protein stabilization and nuclear translocation of YAP/TAZ (YAP/TAZ activation); CTGF production; and cell proliferation. Furthermore, the TIMP-1-YAP/TAZ axis is aberrantly activated in various types of cancer cells or tissues. TIMP-1 knockdown inhibits cell proliferation through YAP/TAZ inactivation in cancer cells. This study found that TIMP-1 accelerates cell proliferation through YAP/TAZ activation in cancer, and suggests the TIMP-1-YAP/TAZ axis may be a novel potential drug target for cancer patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28925394     DOI: 10.1038/onc.2017.321

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

1.  Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein.

Authors:  Ki-Kyung Jung; Xu-Wen Liu; Rosemarie Chirco; Rafael Fridman; Hyeong-Reh Choi Kim
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

Review 2.  Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review.

Authors:  Mie Grunnet; Morten Mau-Sørensen; Nils Brünner
Journal:  Scand J Gastroenterol       Date:  2013-07-08       Impact factor: 2.423

Review 3.  Regulation of the Hippo pathway and implications for anticancer drug development.

Authors:  Hyun Woo Park; Kun-Liang Guan
Journal:  Trends Pharmacol Sci       Date:  2013-09-16       Impact factor: 14.819

4.  A gp130-Src-YAP module links inflammation to epithelial regeneration.

Authors:  Koji Taniguchi; Li-Wha Wu; Sergei I Grivennikov; Petrus R de Jong; Ian Lian; Fa-Xing Yu; Kepeng Wang; Samuel B Ho; Brigid S Boland; John T Chang; William J Sandborn; Gary Hardiman; Eyal Raz; Yoshihiko Maehara; Akihiko Yoshimura; Jessica Zucman-Rossi; Kun-Liang Guan; Michael Karin
Journal:  Nature       Date:  2015-02-25       Impact factor: 49.962

Review 5.  TIMPs: versatile extracellular regulators in cancer.

Authors:  Hartland W Jackson; Virginie Defamie; Paul Waterhouse; Rama Khokha
Journal:  Nat Rev Cancer       Date:  2016-12-09       Impact factor: 60.716

6.  The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage.

Authors:  Sabrina Strano; Olimpia Monti; Natalia Pediconi; Alessia Baccarini; Giulia Fontemaggi; Eleonora Lapi; Fiamma Mantovani; Alexander Damalas; Gennaro Citro; Ada Sacchi; Giannino Del Sal; Massimo Levrero; Giovanni Blandino
Journal:  Mol Cell       Date:  2005-05-13       Impact factor: 17.970

7.  MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis.

Authors:  Yi Tang; R Grant Rowe; Elliot L Botvinick; Abhishek Kurup; Andrew J Putnam; Motoharu Seiki; Valerie M Weaver; Evan T Keller; Steven Goldstein; Jinlu Dai; Dana Begun; Thomas Saunders; Stephen J Weiss
Journal:  Dev Cell       Date:  2013-05-16       Impact factor: 12.270

8.  Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

Authors:  Xiaodong Feng; Maria Sol Degese; Ramiro Iglesias-Bartolome; Jose P Vaque; Alfredo A Molinolo; Murilo Rodrigues; M Raza Zaidi; Bruce R Ksander; Glenn Merlino; Akrit Sodhi; Qianming Chen; J Silvio Gutkind
Journal:  Cancer Cell       Date:  2014-05-29       Impact factor: 31.743

9.  TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway.

Authors:  Guohe Song; Shifeng Xu; Hong Zhang; Yupeng Wang; Chao Xiao; Tao Jiang; Leilei Wu; Tao Zhang; Xing Sun; Lin Zhong; Chongzhi Zhou; Zhaowen Wang; Zhihai Peng; Jian Chen; Xiaoliang Wang
Journal:  J Exp Clin Cancer Res       Date:  2016-09-20

10.  TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling.

Authors:  Sang-A Park; Min-Jin Kim; So-Yeon Park; Jung-Shin Kim; Woosung Lim; Jeong-Seok Nam; Yhun Yhong Sheen
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

View more
  13 in total

1.  A Novel Protective Role for Matrix Metalloproteinase-8 in the Pulmonary Vasculature.

Authors:  Paul B Dieffenbach; Christina Mallarino Haeger; Rakhshinda Rehman; Alexis M Corcoran; Anna Maria F Coronata; Shamsudheen K Vellarikkal; Izabela Chrobak; Aaron B Waxman; Sally H Vitali; Lynette M Sholl; Robert F Padera; David Lagares; Francesca Polverino; Caroline A Owen; Laura E Fredenburgh
Journal:  Am J Respir Crit Care Med       Date:  2021-12-15       Impact factor: 21.405

2.  TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ.

Authors:  Sha Zhou; Shiliang Liu; Chuyong Lin; Yue Li; Liping Ye; Xianqiu Wu; Yunting Jian; Yuhu Dai; Ying Ouyang; Lei Zhao; Mengzhong Liu; Libing Song; Mian Xi
Journal:  Oncogene       Date:  2020-03-10       Impact factor: 9.867

3.  Requirement for epithelial p38α in KRAS-driven lung tumor progression.

Authors:  Jessica Vitos-Faleato; Sebastián M Real; Nuria Gutierrez-Prat; Alberto Villanueva; Elisabet Llonch; Matthias Drosten; Mariano Barbacid; Angel R Nebreda
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-22       Impact factor: 11.205

4.  PLEKHO1 knockdown inhibits RCC cell viability in vitro and in vivo, potentially by the Hippo and MAPK/JNK pathways.

Authors:  Zi Yu; Qiang Li; Gejun Zhang; Chengcheng Lv; Qingzhuo Dong; Cheng Fu; Chuize Kong; Yu Zeng
Journal:  Int J Oncol       Date:  2019-05-30       Impact factor: 5.650

5.  SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.

Authors:  John M Lamar; Yuxuan Xiao; Emily Norton; Zhi-Gang Jiang; Genevieve M Gerhard; Simrin Kooner; Janine S A Warren; Richard O Hynes
Journal:  J Biol Chem       Date:  2018-12-17       Impact factor: 5.157

6.  Impact of transcutaneous neuromuscular electrical stimulation or resistance exercise on skeletal muscle mRNA expression in COPD.

Authors:  Lorna E Latimer; Despina Constantin; Michael C Steiner; Paul L Greenhaff; Neil J Greening; Lori Calvert; Manoj K Menon
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-06-28

7.  SLC1A1, SLC16A9, and CNTN3 Are Potential Biomarkers for the Occurrence of Colorectal Cancer.

Authors:  Jie Zhou; Zhiman Xie; Ping Cui; Qisi Su; Yu Zhang; Lijia Luo; Zhuoxin Li; Li Ye; Hao Liang; Jiegang Huang
Journal:  Biomed Res Int       Date:  2020-05-23       Impact factor: 3.411

8.  A Novel Small Molecular Prostaglandin Receptor EP4 Antagonist, L001, Suppresses Pancreatic Cancer Metastasis.

Authors:  Jiacheng He; Xianhua Lin; Fanhui Meng; Yumiao Zhao; Wei Wang; Yao Zhang; Xiaolei Chai; Ying Zhang; Weiwei Yu; Junjie Yang; Guichao Li; Xuekui Du; Hankun Zhang; Mingyao Liu; Weiqiang Lu
Journal:  Molecules       Date:  2022-02-11       Impact factor: 4.411

Review 9.  YAP/TAZ Activation as a Target for Treating Metastatic Cancer.

Authors:  Janine S A Warren; Yuxuan Xiao; John M Lamar
Journal:  Cancers (Basel)       Date:  2018-04-10       Impact factor: 6.639

10.  Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer.

Authors:  Cathrine Nordgaard; Sophia Doll; Ana Laura de Souza Almeida Matos; Mikkel Høeberg; Julhash Uddin Kazi; Stine Friis; Jan Stenvang; Lars Rönnstrand; Matthias Mann; José Manuel Afonso Moreira
Journal:  Mol Oncol       Date:  2019-10-24       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.